Literature DB >> 33443016

Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients infected with SARS-CoV-2.

Kelsey E Huntington1,2,3,4,5,6,7, Anna D Louie1,2,3,4,8, Chun Geun Lee3,4,7, Jack A Elias3,4,7, Eric A Ross9, Wafik S El-Deiry1,2,3,4,5,6,10.   

Abstract

Although the range of immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is variable, cytokine storm is observed in a subset of symptomatic individuals. To further understand the disease pathogenesis and, consequently, to develop an additional tool for clinicians to evaluate patients for presumptive intervention, we sought to compare plasma cytokine levels between a range of donor and patient samples grouped by a COVID-19 Severity Score (CSS) based on the need for hospitalization and oxygen requirement. Here we utilize a mutual information algorithm that classifies the information gain for CSS prediction provided by cytokine expression levels and clinical variables. Using this methodology, we found that a small number of clinical and cytokine expression variables are predictive of presenting COVID-19 disease severity, raising questions about the mechanism by which COVID-19 creates severe illness. The variables that were the most predictive of CSS included clinical variables such as age and abnormal chest x-ray as well as cytokines such as macrophage colony-stimulating factor, interferon-inducible protein 10, and interleukin-1 receptor antagonist. Our results suggest that SARS-CoV-2 infection causes a plethora of changes in cytokine profiles and that particularly in severely ill patients, these changes are consistent with the presence of macrophage activation syndrome and could furthermore be used as a biomarker to predict disease severity.
© 2021, Huntington et al.

Entities:  

Keywords:  COVID-19; cytokine; human; immunology; inflammation; macrophage activation syndrome; medicine; mutual information algorithm

Year:  2021        PMID: 33443016     DOI: 10.7554/eLife.64958

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  6 in total

1.  Biochemical, biophysical, and immunological characterization of respiratory secretions in severe SARS-CoV-2 infections.

Authors:  Michael J Kratochvil; Gernot Kaber; Sally Demirdjian; Pamela C Cai; Elizabeth B Burgener; Nadine Nagy; Graham L Barlow; Medeea Popescu; Mark R Nicolls; Michael G Ozawa; Donald P Regula; Ana E Pacheco-Navarro; Samuel Yang; Vinicio A de Jesus Perez; Harry Karmouty-Quintana; Andrew M Peters; Bihong Zhao; Maximilian L Buja; Pamela Y Johnson; Robert B Vernon; Thomas N Wight; Carlos E Milla; Angela J Rogers; Andrew J Spakowitz; Sarah C Heilshorn; Paul L Bollyky
Journal:  JCI Insight       Date:  2022-06-22

2.  Integrin/TGF-β1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity.

Authors:  Kelsey E Huntington; Lindsey Carlsen; Eui-Young So; Matthias Piesche; Olin Liang; Wafik S El-Deiry
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-17

3.  Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.

Authors:  Muhammad Bilal Abid
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

4.  Integrin/TGF-β1 inhibitor GLPG-0187 blocks SARS-CoV-2 Delta and Omicron pseudovirus infection of airway epithelial cells which could attenuate disease severity.

Authors:  Kelsey E Huntington; Lindsey Carlsen; Eui-Young So; Matthias Piesche; Olin Liang; Wafik S El-Deiry
Journal:  medRxiv       Date:  2022-01-03

5.  Biochemical, Biophysical, and Immunological Characterization of Respiratory Secretions in Severe SARS-CoV-2 (COVID-19) Infections.

Authors:  Michael J Kratochvil; Gernot Kaber; Sally Demirdjian; Pamela C Cai; Elizabeth B Burgener; Nadine Nagy; Graham L Barlow; Medeea Popescu; Mark R Nicolls; Michael G Ozawa; Donald P Regula; Ana E Pacheco-Navarro; Samuel Yang; Vinicio A de Jesus Perez; Harry Karmouty-Quintana; Andrew M Peters; Bihong Zhao; Maximilian L Buja; Pamela Y Johnson; Robert B Vernon; Thomas N Wight; Carlos E Milla; Angela J Rogers; Andrew J Spakowitz; Sarah C Heilshorn; Paul L Bollyky
Journal:  medRxiv       Date:  2022-04-04

6.  Longitudinally monitored immune biomarkers predict the timing of COVID-19 outcomes.

Authors:  Gorka Lasso; Saad Khan; Stephanie A Allen; Margarette Mariano; Catalina Florez; Erika P Orner; Jose A Quiroz; Gregory Quevedo; Aldo Massimi; Aditi Hegde; Ariel S Wirchnianski; Robert H Bortz; Ryan J Malonis; George I Georgiev; Karen Tong; Natalia G Herrera; Nicholas C Morano; Scott J Garforth; Avinash Malaviya; Ahmed Khokhar; Ethan Laudermilch; M Eugenia Dieterle; J Maximilian Fels; Denise Haslwanter; Rohit K Jangra; Jason Barnhill; Steven C Almo; Kartik Chandran; Jonathan R Lai; Libusha Kelly; Johanna P Daily; Olivia Vergnolle
Journal:  PLoS Comput Biol       Date:  2022-01-18       Impact factor: 4.475

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.